Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FJ1W
|
|||
| Former ID |
DNCL003423
|
|||
| Drug Name |
DE-766
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72] | Phase 3 | [1], [2] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1], [2] | ||
| Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Investigative | [3] | ||
| Company |
Daiichi Sankyo
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Daiichi Sankyo. | |||
| REF 2 | Clinical pipeline report, company report or official report of Daiichi Sankyo. | |||
| REF 3 | Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.